Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/EUCTR2015-002397-21-NL
EUCTR2015-002397-21-NLActive, not recruitingNot Applicable

FOLLOW-UP SAFETY TRIAL IN CHILDREN WITH CHRONIC HEART FAILURE THERAPY RECEIVING ORODISPERSIBLE MINITABLETS OF ENALAPRIL - ENALONG

Ethicare GmbH0 sites100 target enrollmentStarted: October 12, 2015Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Trial Snapshot

Phase
Not Applicable
Status
Active, not recruiting
Enrollment
100
Study OverviewEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional clinical trial of medicinal product

Eligibility Criteria

Sex
All

Inclusion Criteria

  • •Patients from the WP08 and WP09 trials who have been treated with enalapril Orodispersible Minitablets and are still under ODMT treatment.
  • •Patients from the WP08 and WP09 trials who have been treated with at least 3 doses of enalapril Orodispersible Minitablets and are not anymore under ODMT treatment.
  • •Patient and/or parent(s)/legal guardian provided written informed consent for participation in this long term follow-up study.
  • •Are the trial subjects under 18? yes
  • •Number of subjects for this age range: 100
  • •F.1.2 Adults (18-64 years) no
  • •F.1.2.1 Number of subjects for this age range
  • •F.1.3 Elderly (>=65 years) no
  • •F.1.3.1 Number of subjects for this age range

Exclusion Criteria

  • •Patients who have been enrolled and treated in the WP08 or WP09 trials have fulfilled the respective in- and exclusion criteria of those protocols. As it is the aim of this Follow-up Study to observe the safety of all patients exposed to enalapril ODMT treatment, no additional exclusion criteria are defined in this protocol.

Investigators

Similar Trials

Active, not recruiting
Phase 1
FOLLOW-UP SAFETY TRIAL IN CHILDREN WITH CHRONIC HEART FAILURE THERAPY RECEIVING ORODISPERSIBLE MINITABLETS OF ENALAPRIHeart Failure due to Dilated Cardiomyopathy and Congenital Heart DiseaseMedDRA version: 18.1Level: LLTClassification code 10010495Term: Congenital heart disease NOSSystem Organ Class: 100000004850MedDRA version: 18.1Level: LLTClassification code 10056419Term: Dilated cardiomyopathySystem Organ Class: 100000004849
EUCTR2015-002397-21-HUEthicare GmbH100
Active, not recruiting
Phase 1
FOLLOW-UP SAFETY TRIAL IN CHILDREN WITH CHRONIC HEART FAILURE THERAPY RECEIVING ORODISPERSIBLE MINITABLETS OF ENALAPRIHeart Failure due to Dilated Cardiomyopathy and Congenital Heart DiseaseMedDRA version: 20.0Level: LLTClassification code 10010495Term: Congenital heart disease NOSSystem Organ Class: 100000004850MedDRA version: 20.0Level: LLTClassification code 10056419Term: Dilated cardiomyopathySystem Organ Class: 100000004849
EUCTR2015-002397-21-ATEthicare GmbH85
Active, not recruiting
Phase 1
FOLLOW-UP SAFETY TRIAL IN CHILDREN WITH CHRONIC HEART FAILURE THERAPY RECEIVING ORODISPERSIBLE MINITABLETS OF ENALAPRIHeart Failure due to Dilated Cardiomyopathy and Congenital Heart DiseaseMedDRA version: 20.0Level: LLTClassification code 10010495Term: Congenital heart disease NOSSystem Organ Class: 100000011531MedDRA version: 20.0Level: LLTClassification code 10056419Term: Dilated cardiomyopathySystem Organ Class: 100000011725
EUCTR2015-002397-21-DEEthicare GmbH85
Active, not recruiting
Not Applicable
FOLLOW-UP SAFETY TRIAL IN CHILDREN WITH CHRONIC HEART FAILURE THERAPY RECEIVING ORODISPERSIBLE MINITABLETS OF ENALAPRI
EUCTR2015-002397-21-GBEthicare GmbH100
Completed
Phase 2
Follow-up Safety Trial in children with chronic heart failure therapy receiving Orodispersible Minitablets of Enalapril (WP10 Trial).hartaandoeningen, myocardaandoeningen10010394Dilated CardiomyopathyCongenital Heart Disease
NL-OMON46324Ethicare GmbH11